Sangamo slashes time to market for Fabry gene therapy as FDA agrees to accelerated approval package

Sangamo Therapeutics has identified a shortcut to market for its Fabry disease candidate, aligning with the FDA on a pathway that could slash three years from the time to market and free it from the need to run an additional registrational study. Shares in Sangamo jumped 33% to $1.22 in the wake of the news.